

Health Disparities in Hematologic Malignancies: From Genes to Outreach

Weill Cornell Medicine; Belfer Auditorium

June 6-7, 2025

Day 1 - Friday June 6, 2025

7:30 am	Registration and Breakfast:
8:00 am • 8:05	Opening remarks TBD_ Patient Advocate (10 min presentation + 5 min questions)
8:20- 10:05 am • 8:20 • 8:35 • 8:50 • 9:05 • 9:20	Session 1: The impact of germline variants and genomic abnormalities Irene Ghobrial, M.D. Dana Farber Cancer Institute, Boston, MA SU2C MM Dream team (Online study GWAS) Lauren Peres, M.D. Moffit Cancer Center, Tampa, FL MM, risk determinants/Moffit biobank markers; - InterLYMPH- MM Lyndon Mitnaul, Ph.D. Pharmaceuticals, Inc., Tarrytown, New York Together 4 Change Genomics and Equity Initiative. Maureen Murphy, Ph.D. Wistar Institute, Philadelphia, PA Germline variants (p53, HSP) in AA patients Discussion leader: Irene Ghobrial, M.D. Dana Farber Cancer Institute, Boston, MA (45 min call to action-discussion)
10:05 -10:30 am	Coffee Break
10:30-12:00 pm • 10:30 • 10:45 • 11:00 • 11:15	Session 2: Prognostic and therapeutic implications of the molecular landscape- Part A Aaron Viny, M.D. Columbia University, New York, NY Hispanic patients with new molecular variant of leukemia. Wendy Cozen, D.O. University of California, Irvine, CA HL and MM in AA patients Sandeep Dave, M.D. Duke University, Durham, NC Genetic Origins of Adverse Outcomes in African Americans with Lymphoma Discussion leader: Wendy Cozen, D.O. University of California, Irvine, CA (45 min call to action-discussion)

12:00 pm	Lunch
1:30-3:30 pm <ul style="list-style-type: none"> • 1:30 • 1:45 • 2:00 • 2:15 • 2:30 • 2:45 	<p>Session 3: The impact of social determinants of health on outcomes</p> <p>Helen Ma, M.D. UC Irvine; A Long Beach Healthcare System in Long Beach, CA <i>Military exposure in the natural history of lymphoma among veterans</i></p> <p>Alison Walker, M.D. Moffit Cancer Center, Tampa, FL <i>Disparities in AML survival for patients in medically underserved areas</i></p> <p>Theresa Keegan, Ph.D. University of California Davis School of Medicine, Sacramento, CA <i>Sociodemographic disparities in survivorship of Hodgkin’s lymphoma patients</i></p> <p>Oreofe Odejide, M.D. Dana Farber Cancer Institute, Boston, MA <i>Health insurance and end-of-life care for people with hematologic malignancies</i></p> <p>Wellington Fernandes da Silva, M.D. Instituto do Cancer do Estado de São Paulo (ICESP), Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil <i>Management and outcomes of ALL in resource-constrained settings</i></p> <p>Discussion leader: Chijioke Nze, M.D. The University of Texas MD Anderson Cancer Center (45 min call to action-discussion)</p>
3:30 -4:00 pm	Coffee Break
4:00-5:00 pm	<p>Session 4: Developing strategies to increase community representation in clinical enrollment</p> <p>Meghan Gutierrez: Lymphoma Research Foundation <i>Health Equity/ Spanish Language Navigation project</i></p> <p>Mark Fiala, M.D. Washington University School of Medicine, St. Louis, MO <i>Use of patient portals for clinical trial recruitment</i></p> <p>Enrique Diaz, M.D. University of Texas Health Science Center, San Antonio, TX</p> <p>Sikander Ailawadhi, M.D. Mayo Clinic, Jacksonville, FL</p> <p>Discussion leader: Oscar Lahoud, M.D. New York University Langone Hospital, Brooklyn, NY</p>
5:00 -5:45	Patient Advocacy Session
5:45-7:45pm	Poster Session and Happy Hour

Day 2 - Saturday, June 7, 2025

8:00- 8:30 am	Registration and Breakfast
<p>8:30- 8:30 am</p> <ul style="list-style-type: none"> • 8:30 • 8:45 • 9:00 • 9:15 • 9:30 	<p>Session 5: Prognostic and therapeutic implications of the molecular landscape- Part B</p> <p>Rosalie Griffin Ph.D. Mayo Clinic, Rochester, MN <i>Genetic origins of lymphoma and CLL in minorities</i></p> <p>H. Leighton Grimes, Ph.D. Cincinnati Children’s, Hospital, Cincinnati, OH <i>A genetic-genomics dissection of ancestry associated outcomes in acute myeloid leukemia.</i></p> <p>Lawrence Boise, Ph.D. Emory University School of Medicine, Atlanta, GA <i>Defining the landscape of structural alterations in African American Multiple Myeloma</i></p> <p>Nancy Gillis-Johnson, Pharm.D.; Ph.D. Moffit Cancer Center, Tampa, FL <i>Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma</i></p> <p>Discussion leader: Monica Guzman, Ph.D. Weill Cornell Medicine <i>(45 min call to action-discussion)</i></p>
10:15 -10:35 am	Coffee Break
<p>10:35- 12:00 pm</p> <ul style="list-style-type: none"> • 10:35 • 10:50 • 11:05 • 11:20 • 11:35 	<p>Session 6: The burden of lymphoproliferative disorders in Latin America & lower-middle-income countries</p> <p>Carlos Chiattonne, M.D. Faculdade de Ciências Médicas da Santa Casa de São Paulo, Brazil <i>Treatment and outcomes of lymphoma patients in Brazil and LATAM</i></p> <p>Wei-Li Zhao, M.D. Shanghai Institute of Hematology. <i>Impact of myeloid leukemia associated mutations (ASXL1, DNMT3A, TET2, IDH1 and IDH2) on treatment responses among Chronic Myeloid Leukemia (CML) patients in Tanzania</i></p> <p>Robert Baiocchi, M.D. Ohio State University Comprehensive Cancer Center, Chicago, IL <i>EBV+ Lymphomas in Ethiopia</i></p> <p>Rosana Pelayo, Ph.D. Centro de Investigación Biomédica de Oriente (CIBIOR), Instituto Mexicano del Seguro Social (IMSS), Puebla, Mexico <i>Geocoding/environmental associations with increased childhood incidence of ALL in Mexico</i></p> <p>Discussion leader: Guilherme Duffles Amarante, M.D. Faculdade de Ciências Médicas da Santa Casa de São Paulo, Brazil <i>(25 min call to action-discussion)</i></p>
12:00 pm	Lunch

1:15-1:35 pm	<p>Session 7 <i>Project Highlight</i>: The Leukemia & Lymphoma Society's Specialized Center of Research (SCOR) program</p> <p>Jean Koff, M.D., M.S. Emory Winship Cancer Institute, Atlanta, GA <i>Translating molecular profiles into treatment approaches to target disparities in lymphoma</i></p>
<p>1:35 – 2:50 pm</p> <ul style="list-style-type: none"> • 1:35 pm • 1:50 pm • • 2:05 pm • 2:15 pm • 2:25 pm 	<p>Session 8: <i>Developing a funding strategy to address disparities</i></p> <p>Meghan Gutierrez Chief Executive Officer, Lymphoma Research Foundation</p> <p>Michael Yaffe, M.D., Ph.D. Vice President of Research, The Leukemia & Lymphoma Society</p> <p>Lore Gruenbaum, Ph.D. Vice President of the Therapy Acceleration Program, The Leukemia & Lymphoma Society</p> <p>Patricia Frustace Senior Director, Awards & Diversity Programs, American Society of Hematology</p> <p>Deirdra R. Terrell, Ph.D. University of Oklahoma Health Sciences Center; ASH MRI Program</p> <p>Discussion leader: Christopher Flowers, M.D., M.S., FASCO The University of Texas, MD Anderson Cancer Center <i>(40 min call to action-discussion)</i></p>
3:00 -3:15 pm	Coffee Break
3:15 – 4:15 pm	<p>Keynote:</p> <p>Kelou Fox, Ph.D. University of California San Diego, San Diego, CA <i>Indigenous data sovereignty and the implementation of benefit-sharing in biomedical research</i></p>
4:15 -4:20 pm	Closing Remarks
4:20 pm	Adjourn